AstraZeneca Patient Collaboration Defines Patient Centricity

$0.00

In March 2017 AstraZeneca announced it had defined patient centricity – a term that is used a lot in the life sciences industry but without a consistent definition.

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-developed with patients and caregivers using research led by AstraZeneca and patient community advocates to ensure a deep understanding of patient needs and values. Ten associated patient-centric principles were also identified and published in BMJ Innovations to provide the pharmaceutical industry with a consistent reference point to sustain meaningful and mutually beneficial engagement with patients. Wider testing of these outputs among US and European patient communities confirmed their validity.

The research published in BMJ defines patient centricity as: “Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family.” This definition encompassed five clear points of importance to patients that were identified and validated through the research: (1) inclusiveness; (2) sharing goals that are patient and family centred; (3) empowering patients to take control of their own health; (4) working in a way that shows respect, compassion and openness; and (5) working in partnership.

The attached documents are the press release and complete BMJ paper.

Description

In March 2017 AstraZeneca announced it had defined patient centricity – a term that is used a lot in the life sciences industry but without a consistent definition.

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-developed with patients and caregivers using research led by AstraZeneca and patient community advocates to ensure a deep understanding of patient needs and values. Ten associated patient-centric principles were also identified and published in BMJ Innovations to provide the pharmaceutical industry with a consistent reference point to sustain meaningful and mutually beneficial engagement with patients. Wider testing of these outputs among US and European patient communities confirmed their validity.

The research published in BMJ defines patient centricity as: “Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family.” This definition encompassed five clear points of importance to patients that were identified and validated through the research: (1) inclusiveness; (2) sharing goals that are patient and family centred; (3) empowering patients to take control of their own health; (4) working in a way that shows respect, compassion and openness; and (5) working in partnership.

The attached documents are the press release and complete BMJ paper.